Ipamorelin Dosage Guide

Ipamorelin dosing is informed by a combination of clinical pharmacokinetic studies, dose-response trials, and two decades of community experience. Unlike topical peptides, Ipamorelin is dosed in micrograms (mcg) per injection and administered subcutaneously.

Clinical Trials

Early clinical studies by Raun et al. (1998) established Ipamorelin as a potent and selective GH secretagogue in animal models, demonstrating dose-dependent GH release without affecting ACTH or cortisol. Human pharmacokinetic studies tested doses from 1 mcg/kg to 100 mcg/kg intravenously, showing linear dose-response GH elevation. Subsequent studies confirmed that subcutaneous administration at clinically relevant doses produced meaningful GH pulses with minimal side effects.

Pharmacokinetics & Dose-Response

Ipamorelin has a plasma half-life of approximately 2 hours after subcutaneous injection. Peak GH levels occur at 30–40 minutes post-injection. The dose-response relationship shows that GH output increases with dose up to a plateau — doses above 300 mcg do not produce proportionally more GH but may increase side effects. This establishes the practical ceiling at 300 mcg per injection.

Community Consensus

Over 15+ years of community use, the established protocol is 200–300 mcg per injection, 2–3 times per day, with the bedtime dose considered most important due to the natural GH surge during deep sleep. The community also established the fasting requirement (1–2 hours before, 20–30 minutes after) and the preference for stacking with CJC-1295 no DAC for amplified results.

Once you reconstitute your Ipamorelin vial, you need to calculate how many units on your insulin syringe correspond to your target dose in micrograms. This depends on how much bacteriostatic water you added.

Quick Reference — 5 mg Vial

Ipamorelin's mechanism is consistent across goals — it stimulates pulsatile GH release from the pituitary. However, dosing frequency, timing, and stacking vary depending on what you're trying to achieve.

Anti-Aging & General Wellness

Growth hormone naturally declines with age (somatopause). Ipamorelin restores more youthful GH pulsatility without the risks of exogenous HGH. Users in the anti-aging category typically prioritize sleep quality, skin health, recovery, and overall vitality.

• Dose: 100–200 mcg per injection
• Frequency: 1–2x daily (bedtime dose is the priority)
• Stack: Often combined with CJC-1295 no DAC at 100 mcg
• Duration: 8–12 week cycles with 4-week breaks

Fat Loss

GH mobilizes fatty acids from adipose tissue (lipolysis) and shifts metabolism toward fat oxidation. For fat loss, higher frequency dosing produces more GH pulses throughout the day, amplifying the lipolytic effect.

• Dose: 200–300 mcg per injection
• Frequency: 3x daily (morning fasted, post-workout, bedtime)
• Stack: CJC-1295 no DAC at 100 mcg with each injection
• Notes: The morning fasted dose is particularly important for fat loss — GH release during fasting amplifies lipolysis

Muscle Recovery

GH promotes protein synthesis, collagen synthesis, and tissue repair. For recovery from training, the post-workout and bedtime doses are most critical — they align with the body's natural repair windows.

• Dose: 200–300 mcg per injection
• Frequency: 2–3x daily (post-workout + bedtime minimum)
• Stack: CJC-1295 no DAC at 100 mcg; consider adding BPC-157 for connective tissue repair
• Duration: 8–12 weeks; align cycles with training blocks

Sleep Quality

Improved sleep is one of the earliest and most consistent benefits of Ipamorelin. The bedtime dose amplifies the natural nocturnal GH surge during deep (N3) sleep. Users focused primarily on sleep may not need multiple daily doses.

• Dose: 100–200 mcg
• Frequency: Once daily, 30–60 minutes before bed
• Stack: CJC-1295 no DAC at 100 mcg (optional)
• Notes: Avoid eating for 2+ hours before the bedtime dose for maximum effect

Injury Recovery

GH accelerates tissue repair, collagen synthesis, and bone healing. For injury recovery, Ipamorelin is often combined with tissue-repair peptides like BPC-157 and TB-500 for complementary mechanisms.

• Dose: 200–300 mcg per injection
• Frequency: 2–3x daily
• Stack: CJC-1295 no DAC + BPC-157 (250 mcg 2x daily) ± TB-500
• Notes: Ipamorelin works systemically — inject SubQ in the standard sites, not near the injury

Unlike exogenous HGH (which can be run continuously under medical supervision), Ipamorelin works by stimulating your own pituitary gland. Continuous stimulation without breaks can lead to receptor desensitization, meaning the pituitary becomes less responsive over time. Cycling on and off helps maintain receptor sensitivity and ensures consistent results across multiple cycles.

Time of Day Priority

If you cannot inject three times per day, prioritize in this order:

1. Bedtime — amplifies the natural nocturnal GH surge; produces the greatest single-dose impact on sleep quality and recovery
2. Morning (fasted) — GH pulse during fasting maximizes lipolysis; aligns with natural cortisol peak
3. Post-workout — GH pulse during the anabolic recovery window; supports protein synthesis and tissue repair

Common Side Effects

Mild and transient (typically resolve within the first 1–2 weeks):

• Head rush or mild headache — usually from the acute GH pulse; more common with higher doses
• Tingling or numbness in hands and feet (transient paresthesia) — a known effect of GH elevation
• Mild water retention — GH influences sodium and water balance; typically subtle and temporary
• Injection site redness or mild irritation — normal subcutaneous response
• Increased appetite — mild compared to GHRP-6, but some users notice slight hunger after injection

Less common (usually dose-related):

• Lightheadedness or flushing — more common when injecting at higher doses (>300 mcg) or without adequate hydration
• Vivid dreams — associated with enhanced deep sleep from the bedtime dose
• Joint stiffness — related to GH-mediated water retention in connective tissue; typically mild

Contraindications

• Active cancer or history of cancer — GH and IGF-1 can promote cell proliferation. Do not use Ipamorelin (or any GH secretagogue) if you have active cancer or a recent history of malignancy. Consult an oncologist
• Diabetes (Type 1 or poorly controlled Type 2) — GH antagonizes insulin and can worsen glycemic control. If you have diabetes or pre-diabetes, discuss with your endocrinologist and monitor fasting glucose closely
• Pituitary disorders — Ipamorelin works by stimulating the pituitary. If your pituitary gland is compromised (e.g., pituitary adenoma, hypopituitarism), response will be unpredictable. Medical evaluation is required
• Pregnancy and breastfeeding — no safety data; do not use
• Children and adolescents — no established pediatric safety data for research peptide use; growth hormone regulation in growing individuals requires medical oversight

Drug Interactions

• Insulin and oral hypoglycemics — GH elevation antagonizes insulin. Monitor blood glucose carefully if using diabetes medications
• Corticosteroids — chronic corticosteroid use blunts GH response and may reduce Ipamorelin efficacy
• Exogenous GH (HGH) — using Ipamorelin alongside injected HGH is redundant and increases the risk of GH-related side effects. Choose one approach
• Other GH secretagogues — stacking multiple GHRPs (e.g., Ipamorelin + GHRP-6) increases side effect burden without proportional benefit. Stack with a GHRH analog (CJC-1295 no DAC) instead

Blood Markers to Monitor

• IGF-1 — downstream marker of GH activity; should rise during a cycle. If significantly above reference range, reduce dose
• Fasting glucose & HbA1c — GH can reduce insulin sensitivity; monitor especially if pre-diabetic or stacking with MK-677
• Fasting insulin — elevated insulin with rising glucose suggests developing insulin resistance
• Complete blood count (CBC) — general health marker
• Lipid panel — GH can influence lipid metabolism
• Liver enzymes (AST/ALT) — baseline safety monitoring